Bioreactor technologies to support liver function in vitro

Advanced Drug Delivery Reviews

Volumn 69-70, Issue , 2014, Pages 132-157

  Ebrahimkhani, Mohammad R ^a   Neiman, Jaclyn A Shepard ^a   Raredon, Micha Sam B ^a   Hughes, David J ^b   Griffith, Linda G ^a  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b Centre for Innovation and Enterprise   (United Kingdom)

Author keywords

Bioreactor; Drug development; Drug toxicity; Hepatocytes; Liver non parenchymal cells; Microfluidic; Organ on chip; Tissue engineering

Indexed keywords

BIOCONVERSION; BIOREACTORS; DISEASE CONTROL; DRUG PRODUCTS; DRUG THERAPY; METABOLISM; MICROFLUIDICS; NUCLEIC ACIDS; PHYSIOLOGY; TISSUE ENGINEERING; TOXICITY;

DRUG DEVELOPMENT; EMERGING TECHNOLOGIES; EXPERIMENTAL MODELS; HEPATOCYTES; LIVER-SPECIFIC FUNCTIONS; ON CHIPS; SMALL-MOLECULE DRUGS; TARGETED THERAPEUTICS;

PHYSIOLOGICAL MODELS;

ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT; BIOMATERIAL; TOCILIZUMAB;

BIOREACTOR; BIOTECHNOLOGY; CANCER CHEMOTHERAPY; CELL SUSPENSION; DISEASE MODEL; DRUG DESIGN; DRUG DEVELOPMENT; DRUG METABOLISM; DRUG RESEARCH; DRUG TOXICITY; GENETIC POLYMORPHISM; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; LIVER CELL; LIVER DISEASE; LIVER FUNCTION; LIVER METABOLISM; LIVER METASTASIS; LIVER PARENCHYMA; LIVER PROTECTION; LIVER STRUCTURE; MICROFLUIDICS; MICROTECHNOLOGY; MONOLAYER CULTURE; NANOMEDICINE; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TISSUE CULTURE; TISSUE ENGINEERING; ANIMAL; CULTURE TECHNIQUE; LIVER; ORGAN CULTURE TECHNIQUE; PHYSIOLOGY; PROCEDURES; TRENDS;

ANIMALS; BIOREACTORS; CELL CULTURE TECHNIQUES; HEPATOCYTES; HUMANS; LIVER; ORGAN CULTURE TECHNIQUES;

EID: 84899986727     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.02.011     Document Type: Review

References (225)

1. Godoy P., Hewitt N.J., Albrecht U., Andersen M.E., Ansari N., Bhattacharya S., et al. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch. Toxicol. 2013, 87:1315-1530.
2. LeCluyse E.L., Witek R.P., Andersen M.E., Powers M.J. Organotypic liver culture models: meeting current challenges in toxicity testing. Crit. Rev. Toxicol. 2012, 42:501-548.
3. van Midwoud P.M., Verpoorte E., Groothuis G.M.M. Microfluidic devices for in vitro studies on liver drug metabolism and toxicity. Integr. Biol. (Camb.) 2011, 3:509.
4. Griffith L.G., Swartz M.A. Capturing complex 3D tissue physiology in vitro. Nat. Rev. Mol. Cell Biol. 2006, 7:211-224.
5. Goral V.N., Yuen P.K. Microfluidic platforms for hepatocyte cell culture: new technologies and applications. Ann. Biomed. Eng. 2011, 40:1244-1254.
6. Lautt W.W. Hepatic Circulation: Physiology and Pathophysiology 2009, Morgan & Claypool Publishers.
7. Hofmann A.F., Hagey L.R. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell. Mol. Life Sci. 2008, 65:2461-2483.
8. Halilbasic E., Claudel T., Trauner M. Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J. Hepatol. 2013, 58:155-168.
9. Lumsden A.B., Michael J., Kutner H. Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. Hepatology 1988, 8:232-236.
10. Liaskou E., Wilson D.V., Oo Y.H. Innate immune cells in liver inflammation. Mediat. Inflamm. 2012, (2012):949157.
11. Crispe I.N. The liver as a lymphoid organ. Annu. Rev. Immunol. 2009, 27:147-163.
12. Ohtani O., Ohtani Y. Lymph circulation in the liver. Anat. Rec. 2008, 291:643-652.
13. Friedman S.L. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol. Rev. 2008, 88:125-172.
14. Cogger V.C., McNerney G.P., Nyunt T., DeLeve L.D., McCourt P., Smedsrød B., et al. Three-dimensional structured illumination microscopy of liver sinusoidal endothelial cell fenestrations. J. Struct. Biol. 2010, 171:382-388.
15. Wack K.E., Ross M.A., Zegarra V., Sysko L.R., Watkins S.C., Stolz D.B. Sinusoidal ultrastructure evaluated during the revascularization of regenerating rat liver. Hepatology 2001, 33:363-378.
16. Reid L.M., Fiorino A.S., Sigal S.H., Brill S., Holst P.A. Extracellular matrix gradients in the space of Disse: relevance to liver biology. Hepatology 1992, 15:1198-1203.
17. Ebrahimkhani M.R., Elsharkawy A.M., Mann D.A. Wound healing and local neuroendocrine regulation in the injured liver. Expert Rev. Mol. Med. 2008, 10:e11.
18. Mackay I.R. Hepatoimmunology: a perspective. Immunol. Cell Biol. 2002, 80:36-44.
19. Turner R., Lozoya O., Wang Y., Cardinale V., Gaudio E., Alpini G., et al. Human hepatic stem cell and maturational liver lineage biology. Hepatology 2011, 53:1035-1045.
20. Xia X., Francis H., Glaser S., Alpini G., LeSage G. Bile acid interactions with cholangiocytes. World J. Gastroenterol. 2006, 12:3553-3563.
21. Klein I., Cornejo J.C., Polakos N.K., John B., Wuensch S.A., Topham D.J., et al. Kupffer cell heterogeneity: functional properties of bone marrow derived and sessile hepatic macrophages. Blood 2007, 110:4077-4085.
22. Gao B., Radaeva S., Park O. Liver natural killer and natural killer T cells : immunobiology and emerging roles in liver diseases. J. Leukoc. Biol. 2009, 86:513-528.
23. Panesar N., Tolman K., Mazuski J.E. Endotoxin stimulates hepatocyte interleukin-6 production. J. Surg. Res. 1999, 85:251-258.
24. Seki E., Brenner D.A. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 2008, 48:322-335.
25. Ebrahimkhani M.R., Mohar I., Crispe I.N. Cross-presentation of antigen by diverse subsets of murine liver cells. Hepatology 2011, 54:1379-1387.
26. Höchst B., Schildberg F.A., Böttcher J., Metzger C., Huss S., Türler A., et al. Liver sinusoidal endothelial cells contribute to CD8 T cell tolerance toward circulating carcinoembryonic antigen in mice. Hepatology 2012, 56:1924-1933.
27. Knolle P., Schlaak J., Uhriq A., Kempf P., Meyer zum Büschenfelde K.H., Gerken G. Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge. J. Immunol. 1995, 22:226-229.
28. Knolle P.A., Germann T., Treichel U., Uhrig A., Schmitt E., Hegenbarth S., et al. Endotoxin down-regulates T cell activation by antigen-presenting liver sinusoidal endothelial cells. J. Immunol. 1999, 162:1401-1407.
29. Biswas S.K., Lopez-Collazo E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol. 2009, 30:475-487.
30. Lynch T., Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am. Fam. Physician 2007, 76:391-396.
31. Liddle C., Stedman C.A.M. Hepatic metabolism of drugs. Textb. Hepatol. From Basic Sci. to Clin. Pract. 2007, 241-249. Wiley-Blackwell. 3rd edition. J. Rodes, J.-P. Benhamou, A. Blei, J. Reichen, M. Rizzetto (Eds.).
32. Jakoby W.B., Ziegler D.M. The enzymes of detoxication. J. Biol. Chem. 1990, 265:20715-20718.
33. Commandeur J., Stijntjes G., Vermeulen N. Enzymes formation and transport and systems involved in the of glutathione. Pharmacol. Rev. 1995, 47:271-330.
34. Faber K.N., Müller M., Jansen P.L. Drug transport proteins in the liver. Adv. Drug Deliv. Rev. 2003, 55:107-124.
35. International Transporter Consortium, Giacomini K.M., Huang S.M., Tweedie D.J., Benet L.Z., Brouwer K.L., et al. Membrane transporters in drug development. Nat. Rev. Drug. Discov. 2010, 9:215-236.
36. Olson H., Betton G., Robinson D., Thomas K., Monro A., Kolaja G., et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 2000, 32:56-67.
37. Dash A., Inman W., Hoffmaster K., Sevidal S., Kelly J., Obach R.S., et al. Liver tissue engineering in the evaluation of drug safety. Expert Opin. Drug Metab. Toxicol. 2009, 5:1159-1174.
38. Marion T.L., Leslie E.M., Brouwer K.L.R. Use of sandwich-cultured hepatocytes to evaluate impaired bile acid transport as a mechanism of drug-induced hepatotoxicity. Mol. Pharm. 2007, 4:911-918.
39. Griffin S.J., Houston J.B. Prediction of in vitro intrinsic clearance from hepatocytes: comparison of suspensions and monolayer cultures. Drug Metab. Dispos. 2005, 33:115-120.
40. Greer M.L., Barber J., Eakins J., Kenna J.G. Cell based approaches for evaluation of drug-induced liver injury. Toxicology 2010, 268:125-131.
41. O'Brien P.J., Irwin W., Diaz D., Howard-Cofield E., Krejsa C.M., Slaughter M.R., et al. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol. 2006, 80:580-604.
42. Xu J.J., Henstock P.V., Dunn M.C., Smith A.R., Chabot J.R., de Graaf D. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci. 2008, 105:97-105.
43. Cosgrove B.D., King B.M., Hasan M.A., Alexopoulos L.G., Farazi P.A., Hendriks B.S., et al. Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol. Appl. Pharmacol. 2009, 237:317-330.
44. Kostadinova R., Boess F., Applegate D., Suter L., Weiser T., Singer T., et al. A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity. Toxicol. Appl. Pharmacol. 2013, 268:1-16.
45. Rehermann B., Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 2005, 5:215-229.
46. Gripon P., Rumin S., Urban S., Le Seyec J., Glaise D., Cannie I., et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:15655-15660.
47. Wilson G.K., Stamataki Z. In vitro systems for the study of hepatitis C virus infection. Int. J. Hepatol. 2012, (2012). (Article ID 292591).
48. Ananthanarayanan A., Narmada B.C., Mo X., McMillian M., Yu H. Purpose-driven biomaterials research in liver-tissue engineering. Trends Biotechnol. 2011, 29:110-118.
49. Nahmias Y., Berthiaume F., Yarmush M.L. Integration of technologies for hepatic tissue engineering. Adv. Biochem. Eng. Biotechnol. 2007, 103:309-329.
50. Wagner B.A., Venkataraman S., Buettner G.R. The rate of oxygen utilization by cells. Free Radic. Biol. Med. 2011, 51:700-712.
51. Wiig H., Swartz M.A. Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer. Physiol. Rev. 2012, 92:1005-1060.
52. Gebhardt R., Mecke D. Perifused monolayer cultures of rat hepatocytes as an improved in vitro system for studies on ureogenesis. Exp. Cell Res. 1979, 124:349-359.
53. Dich J., Grunnet N. A perifusion system for cultured hepatocytes. Anal. Biochem. 1992, 206:68-72.
54. Uchino J., Tsuburaya T., Kumagi F., Hase T., Hamada T., Komai T., et al. A hybrid artificial liver composed of multiplated hepatocyte monolayers. Am. Soc. Artif. Intern. Organs Trans. 1988, 34:972-977.
55. Taguchi K., Matsushita M., Takahashi M., Uchino J. Development of a bioartificial liver with sandwiched-cultured hepatocytes between two collagen gel layers. Artif. Organs 1996, 20:178-185.
56. Kan P., Miyoshi H., Yanagi K., Ohshima N. Effects of shear stress on metabolic function of the co-culture system of hepatocyte/nonparenchymal cells for a bioartificial liver. ASAIO J. 1998, 44:M441-M444.
57. Kan P., Miyoshi H., Ohshima N. Perfusion of medium with supplemented growth factors changes metabolic activities and cell morphology of hepatocyte-nonparenchymal cell coculture. Tissue Eng. 2004, 10:1297-1307.
58. Tilles A.W., Baskaran H., Roy P., Yarmush M.L., Toner M. Effects of oxygenation and flow on the viability and function of rat hepatocytes cocultured in a microchannel flat-plate bioreactor. Biotechnol. Bioeng. 2001, 73:379-389.
59. Park J., Berthiaume F., Toner M., Yarmush M.L., Tilles A.W. Microfabricated grooved substrates as platforms for bioartificial liver reactors. Biotechnol. Bioeng. 2005, 90:632-644.
60. Allen J.W., Bhatia S.N. Formation of steady-state oxygen gradients in vitro: application to liver zonation. Biotechnol. Bioeng. 2003, 82:253-262.
61. Allen J.W., Khetani S.R., Bhatia S.N. In vitro zonation and toxicity in a hepatocyte bioreactor. Toxicol. Sci. 2005, 84:110-119.
62. Nishikawa M., Kojima N., Komori K., Yamamoto T., Fujii T., Sakai Y. Enhanced maintenance and functions of rat hepatocytes induced by combination of on-site oxygenation and coculture with fibroblasts. J. Biotechnol. 2008, 133:253-260.
63. Regehr K.J., Domenech M., Koepsel J.T., Carver K.C., Ellison-Zelski S.J., Murphy W.L., et al. Biological implications of polydimethylsiloxane-based microfluidic cell culture. Lab Chip 2009, 9:2132-2139.
64. van Midwoud P.M., Janse A., Merema M.T., Groothuis G.M.M., Verpoorte E. Comparison of biocompatibility and adsorption properties of different plastics for advanced microfluidic cell and tissue culture models. Anal. Chem. 2012, 84:3938-3944.
65. Williams C.M., Mehta G., Peyton S.R., Zeiger A.S., Van Vliet K.J., Griffith L.G. Autocrine-controlled formation and function of tissue-like aggregates by primary hepatocytes in micropatterned hydrogel arrays. Tissue Eng. A. 2011, 17:1055-1068.
66. Mazzei D., Guzzardi M.A., Giusti S., Ahluwalia A. A low shear stress modular bioreactor for connected cell culture under high flow rates. Biotechnol. Bioeng. 2010, 106:127-137.
67. Xia L., Ng S., Han R., Tuo X., Xiao G., Leo H.L., et al. Laminar-flow immediate-overlay hepatocyte sandwich perfusion system for drug hepatotoxicity testing. Biomaterials 2009, 30:5927-5936.
68. Dash A., Simmers M.B., Deering T.G., Berry D.J., Feaver R.E., Hastings N.E., et al. Hemodynamic flow improves rat hepatocyte morphology, function, and metabolic activity in vitro. Am. J. Physiol. Cell Physiol. 2013, 304:C1053-C1063.
69. De Bartolo L., Jarosch-Von Schweder G., Haverich A., Bader A. A novel full-scale flat membrane bioreactor utilizing porcine hepatocytes: cell viability and tissue-specific functions. Biotechnol. Prog. 2000, 16:102-108.
70. De Bartolo L., Salerno S., Morelli S., Giorno L., Rende M., Memoli B., et al. Long-term maintenance of human hepatocytes in oxygen-permeable membrane bioreactor. Biomaterials 2006, 27:4794-4803.
71. Vinci B., Duret C., Klieber S., Gerbal-Chaloin S., Sa-Cunha A., Laporte S., et al. Modular bioreactor for primary human hepatocyte culture: medium flow stimulates expression and activity of detoxification genes. Biotechnol. J. 2011, 6:554-564.
72. Buck L.D., Inman S.W., Rusyn I., Griffith L.G. Co-regulation of primary mouse hepatocyte viability and function by oxygen and matrix. Biotechnol. Bioeng. 2013, 10.1002/bit.25152.
73. Leclerc E., Sakai Y., Fujii T. Cell culture in 3-dimensional microfluidic structure of PDMS (polydimethylsiloxane). Biomed. Microdevices 2003, 1:109-114.
74. Leclerc E., Sakai Y., Fujii T. Perfusion culture of fetal human hepatocytes in microfluidic environments. Biochem. Eng. J. 2004, 20:143-148.
75. Carraro A., Hsu W.-M., Kulig K.M., Cheung W.S., Miller M.L., Weinberg E.J., et al. In vitro analysis of a hepatic device with intrinsic microvascular-based channels. Biomed. Microdevices 2008, 10:795-805.
76. Ostrovidov S., Jiang J., Sakai Y., Fujii T. Membrane-based PDMS microbioreactor for perfused 3D primary rat hepatocyte cultures. Biomed. Microdevices 2004, 6:279-287.
77. Sin A., Chin K.C., Jamil M.F., Kostov Y., Rao G., Shuler M.L. The design and fabrication of three-chamber microscale cell culture analog devices with integrated dissolved oxygen sensors. Biotechnol. Prog. 2004, 20:338-345.
78. Viravaidya K., Sin A., Shuler M.L. Development of a microscale cell culture analog to probe naphthalene toxicity. Biotechnol. Prog. 2004, 20:316-323.
79. Leclerc E., Sakai Y., Fujii T. Microfluidic PDMS (polydimethylsiloxane) bioreactor for large-scale culture of hepatocytes. Biotechnol. Prog. 2004, 20:750-755.
80. Prot J.M., Aninat C., Griscom L., Razan F., Brochot C., Guillouzo C.G., et al. Improvement of HepG2/C3a cell functions in a microfluidic biochip. Biotechnol. Bioeng. 2011, 108:1704-1715.
81. Prot J.M., Briffaut A.-S., Letourneur F., Chafey P., Merlier F., Grandvalet Y., et al. Integrated proteomic and transcriptomic investigation of the acetaminophen toxicity in liver microfluidic biochip. PLoS One 2011, 6:e21268.
82. Baudoin R., Griscom L., Prot J.M., Legallais C., Leclerc E. Behavior of HepG2/C3A cell cultures in a microfluidic bioreactor. Biochem. Eng. J. 2011, 53:172-181.
83. Ouattara D.A., Prot J.-M., Bunescu A., Dumas M.-E., Elena-Herrmann B., Leclerc E., et al. Metabolomics-on-a-chip and metabolic flux analysis for label-free modeling of the internal metabolism of HepG2/C3A cells. Mol. Biosyst. 2012, 8:1908-1920.
84. Prot J.-M., Bunescu A., Elena-Herrmann B., Aninat C., Snouber L.C., Griscom L., et al. Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol. Appl. Pharmacol. 2012, 259:270-280.
85. Baudoin R., Alberto G., Legendre A., Paullier P., Naudot M., Leclerc E. Investigation of expression and activity levels of primary rat hepatocyte detoxication genes under various flow rates and cell densities in microfluidic biochips. Biotechnol. Prog. 2013, 33.
86. Legendre A., Baudoin R., Alberto G., Paullier P., Naudot M., Bricks T., et al. Metabolic characterization of primary rat hepatocytes cultivated in parallel microfluidic biochips. J. Pharm. Sci. 2013, 102:3264-3276.
87. Prot J.-M., Videau O., Brochot C., Legallais C., Bénech H., Leclerc E. A cocktail of metabolic probes demonstrates the relevance of primary human hepatocyte cultures in a microfluidic biochip for pharmaceutical drug screening. Int. J. Pharm. 2011, 408:67-75.
88. Inamdar N.K., Griffith L.G., Borenstein J.T. Transport and shear in a microfluidic membrane bilayer device for cell culture. Biomicrofluidics 2011, 5:22213.
89. Tanaka Y., Yamato M., Okano T., Kitamori T., Sato K. Evaluation of effects of shear stress on hepatocytes by a microchip-based system. Meas. Sci. Technol. 2006, 17:3167-3170.
90. Kane B.J., Zinner M.J., Yarmush M.L., Toner M. Liver-specific functional studies in a microfluidic array of primary mammalian hepatocytes. Anal. Chem. 2006, 78:4291-4298.
91. Novik E., Maguire T., Chao P., Cheng K.-C., Yarmush M.L. A microfluidic hepatic coculture platform for cell-based drug metabolism studies. Biochem. Pharmacol. 2010, 79:1036-1044.
92. Sung J.H., Choi J., Kim D., Shuler M.L. Fluorescence optical detection in situ for real-time monitoring of cytochrome P450 enzymatic activity of liver cells in multiple microfluidic devices. Biotechnol. Bioeng. 2009, 104:516-525.
93. Di L., Feng B., Goosen T.C., Lai Y., Steyn S.J., Varma M.V., et al. A perspective on the prediction of drug pharmacokinetics and disposition in drug research and development. Drug Metab. Dispos. 2013, 41:1975-1993.
94. Shuler M.L. Modeling life. Ann. Biomed. Eng. 2012, 40:1399-1407.
95. Sung J.H., Kam C., Shuler M.L. A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip. Lab Chip 2010, 10:446.
96. Sung J.H., Shuler M.L. A micro cell culture analog (microCCA) with 3-D hydrogel culture of multiple cell lines to assess metabolism-dependent cytotoxicity of anticancer drugs. Lab Chip. 2009, 9:1385-1394.
97. Wolf C., Munkelt B. Bilirubin conjugation by an artificial liver composed of cultured cells and synthetic capillaries. ASAIO J. 1975, 21:16-27.
98. Hoffmann S.A., Müller-Vieira U., Biemel K., Knobeloch D., Heydel S., Lübberstedt M., et al. Analysis of drug metabolism activities in a miniaturized liver cell bioreactor for use in pharmacological studies. Biotechnol. Bioeng. 2012, 109:3172-3181.
99. Knazek R.A., Gullino P.M., Kohler P.O., Dedrick R.L. Cell culture on artificial capillaries: an approach to tissue growth in vitro. Science 1972, 178:65-67. (80-).
100. Tapia F., Vogel T., Genzel Y., Behrendt I., Hirschel M., Gangemi J.D., et al. Production of high-titer human influenza A virus with adherent and suspension MDCK cells cultured in a single-use hollow fiber bioreactor. Vaccine 2013, 1-9.
101. Rutzky L.P., Tomita J.T., Calenoff M.A., Kahan B.D. Human colon adenocarcinoma cells. III. In vitro organoid expression and carcinoembryonic antigen kinetics in hollow fiber culture. J. Natl. Cancer Inst. 1979, 63:893-902.
102. Jauregui H., Naik S., Santangini H., Pan J., Trenkler D., Mullon C.J. Primary cultures of rat hepatocytes in hollow fiber chambers. Vitro Cell. Dev. Biol. Anim. 1994, 30A:23-29.
103. Rozga J., Williams F., Ro M.S., Neuzil D.F., Giorgio T.D., Backfisch G., et al. Development of a bioartificial liver: properties and function of a hollow-fiber module inoculated with liver cells. Hepatology 1993, 17:258-265.
104. Jauregui H.O., Mullon C.J., Trenkler D., Naik S., Santangini H., Press P., et al. In vivo evaluation of a hollow fiber liver assist device. Hepatology 1995, 21:460-469.
105. Demetriou A.A., Brown R.S., Busuttil R.W., Fair J., McGuire B.M., Rosenthal P., et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann. Surg. 2004, 239:660-670.
106. Sussman N.L., Chong M.G., Koussayer T., He D.E., Shang T.A., Whisennand H.H., et al. Reversal of fulminant hepatic failure using an extracorporeal liver assist device. Hepatology 1992, 16:60-65.
107. Nyberg S.L., Shatford R.A., Peshwa M.V., White J.G., Cerra F.B., Hu W.S. Evaluation of a hepatocyte-entrapment hollow fiber bioreactor: a potential bioartificial liver. Biotechnol. Bioeng. 1993, 41:194-203.
108. Rozga J., Morsiani E., Lepage E., Moscioni A.D., Demetriou A., Giorgio T. Isolated hepatocytes in a bioartificial liver: a single group view and experience. Biotechnol. Bioeng. 1994, 43:645-653.
109. Rozga J., Demetriou A. Artificial liver. Evolution and future perspectives. ASAIO J. 1995, 41:831-837.
110. Detry O., Arkadopoulos N., Ting P., Kahaku E., Watanabe F., Rozga J., et al. Clinical use of a bioartificial liver to treat acetaminophen-induced fulminant hepatic failure. Am. Surg. 1999, 65:934-938.
111. Gerlach J.C., Zeilinger K., Patzer Ii J.F. Bioartificial liver systems: why, what, whither?. Regen. Med. 2008, 3:575-595.
112. Struecker B., Raschzok N., Sauer I. Liver support strategies: cutting-edge technologies. Nat. Rev. Gastroenterol. Hepatol. 2013, 10.1038/nrgastro.2013.204.
113. Planchamp C., Vu T.L., Mayer J.M., Reist M., Testa B. Hepatocyte hollow-fibre bioreactors: design, set-up, validation and applications. J. Pharm. Pharmacol. 2003, 55:1181-1198.
114. Pless G. Artificial and bioartificial liver support. Organogenesis 2007, 3:20-24.
115. Carpentier B., Gautier A., Legallais C. Artificial and bioartificial liver devices: present and future. Gut 2009, 58:1690-1702.
116. Hoekstra R., Nibourg G.A., van der Hoeven T.V., Plomer G., Seppen J., Ackermans M.T., et al. Phase 1 and phase 2 drug metabolism and bile acid production of HepaRG cells in a bioartificial liver in absence of dimethyl sulfoxide. Drug Metab. Dispos. 2013, 41:562-567.
117. Sauer I.M., Obermeyer N., Kardassis D., Theruvath T., Gerlach J.C. Development of a hybrid liver support system. Ann. N. Y. Acad. Sci. 2001, 944:308-319.
118. Zeilinger K., Holland G., Sauer I.M., Efimova E., Kardassis D., Obermayer N., et al. Time course of primary liver cell reorganization in three-dimensional high-density bioreactors for extracorporeal liver support: an immunohistochemical and ultrastructural study. Tissue Eng. 2004, 10:1113-1124.
119. Lübberstedt M., Müller-Vieira U., Biemel K., Darnell M., Hoffmann S., Knospel F., et al. Serum-free culture of primary human hepatocytes in a miniaturized hollow-fibre membrane bioreactor for pharmacological in vitro studies. J. Tissue Eng. Regen. Med. 2012, 10.1002/term.1652.
120. Darnell M., Schreiter T., Zeilinger K., Urbaniak T., Soderdahl T., Rossberg I., et al. Cytochrome P450-dependent metabolism in HepaRG cells cultured in a dynamic three-dimensional bioreactor. Drug Metab. Dispos. 2011, 39:1131-1138.
121. Lübberstedt M., Müller-Vieira U., Mayer M., Biemel K.M., Knöspel F., Knobeloch D., et al. HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro. J. Pharmacol. Toxicol. Methods 2010, 63:59-68.
122. Zeilinger K., Schreiter T., Darnell M., Söderdahl T., Lübberstedt M., Dillner B., et al. Scaling down of a clinical three-dimensional perfusion multicompartment hollow fiber liver bioreactor developed for extracorporeal liver support to an analytical scale device useful for hepatic pharmacological in vitro studies. Tissue Eng. Part C Methods 2011, 17:549-556.
123. Schmelzer E., Triolo F. Three-dimensional perfusion bioreactor culture supports differentiation of human fetal liver cells. Tissue Eng. A. 2010, 16:2007-2016.
124. Ring A., Gerlach J.C., Peters G., Pazin B.J., Minervini C.F., Turner M.E., et al. Hepatic maturation of human fetal hepatocytes in four-compartment three-dimensional perfusion culture. Tissue Eng. Part C Methods 2010, 16:835-845.
125. Flendrig L., Velde A., Chamuleau R. Semipermeable hollow fiber membranes in hepatocyte bioreactors: a prerequisite for a successful bioartificial liver?. Artif. Organs 1997, 21:2007-2016.
126. Mareels G., Poyck P.P., Eloot S., Chamuleau R.A., Verdonck P.R. Three-dimensional numerical modeling and computational fluid dynamics simulations to analyze and improve oxygen availability in the AMC bioartificial liver. Ann. Biomed. Eng. 2006, 34:1729-1744.
127. Poyck P.P., Hoekstra R., Vermeulen J.L., van Wijk A.C., Chamuleau R.A., Hakvoort T.B., et al. Expression of glutamine synthetase and carbamoylphosphate synthetase I in a bioartificial liver: markers for the development of zonation in vitro. Cells Tissues Organs 2008, 188:259-269.
128. Poyck P.P., Mareels G., Hoekstra R., van Wijk A.C., van der Hoeven T.V., van Gulik T.M., et al. Enhanced oxygen availability improves liver-specific functions of the AMC bioartificial liver. Artif. Organs 2008, 32:116-126.
129. Poyck P.P.C., Hoekstra R., van Wijk A.C., Attanasio C., Calise F., Chamuleau R.A., et al. Functional and morphological comparison of three primary liver cell types cultured in the AMC bioartificial liver. Liver Transpl. 2007, 13:589-598.
130. Nibourg G.A., Chamuleau R.A., van der Hoeven T.V., Maas M.A.W., Ruiter A.F.C., Lamers W.H., et al. Liver progenitor cell line HepaRG differentiated in a bioartificial liver effectively supplies liver support to rats with acute liver failure. PLoS One 2012, 7:e38778.
131. Nibourg G.A., Boer J.D., van der Hoeven T.V., Ackermans M.T., van Gulik T.M., Chamuleau R.A., et al. Perfusion flow rate substantially contributes to the performance of the HepaRG-AMC-bioartificial liver. Biotechnol. Bioeng. 2012, 109:3182-3188.
132. Poyck P., Pless G., Hoekstra R., Roth S., Van Wijk A., Schwartländer R., et al. In vitro comparison of two bioartificial liver support systems: MELS cell module and AMC-BAL. Int. J. Artif. Organs 2007, 30:183-191.
133. Powers M.J., Rodriguez R.E., Griffith L.G. Cell-substratum adhesion strength as a determinant of hepatocyte aggregate morphology. Biotechnol. Bioeng. 1997, 53:415-426.
134. Lillegard J.B., Fisher J.E., Nedredal G., Luebke-Wheeler J., Bao J., Wang W., et al. Normal atmospheric oxygen tension and the use of antioxidants improve hepatocyte spheroid viability and function. J. Cell. Physiol. 2011, 226:2987-2996.
135. Wu F.J., Friend J.R., Hsiao C.C., Zilliox M.J., Ko W.J., Cerra F.B., et al. Efficient assembly of rat hepatocyte spheroids for tissue engineering applications. Biotechnol. Bioeng. 1996, 50:404-415.
136. Tostões R.M., Leite S.B., Serra M., Jensen J., Björquist P., Carrondo M.J.T., et al. Human liver cell spheroids in extended perfusion bioreactor culture for repeated-dose drug testing. Hepatology 2012, 55:1227-1236.
137. Sivaraman A., Leach J.K., Townsend S., Iida T., Hogan B.J., Stolz D.B., et al. A microscale in vitro physiological model of the liver: predictive screens for drug metabolism and enzyme induction. Curr. Drug Metab. 2005, 6:569-591.
138. Powers M.J., Janigian D.M., Wack K.E., Baker C.S., Beer Stolz D., Griffith L.G. Functional behavior of primary rat liver cells in a three-dimensional perfused microarray bioreactor. Tissue Eng. 2002, 8:499-513.
139. Powers M.J., Domansky K., Kaazempur-mofrad M.R., Kalezi A., Capitano A., Upadhyaya A., et al. A microfabricated array bioreactor for perfused 3D liver culture. Biotechnol. Bioeng. 2002, 5:257-269.
140. Hadi M., Westra I.M., Starokozhko V., Dragovic S., Merema M.T., Groothuis G.M. Human precision-cut liver slices as an ex vivo model to study idiosyncratic drug-induced liver injury. Chem. Res. Toxicol. 2013, 26:710-720.
141. Elferink M., Olinga P., Draaisma A., Merema M., Bauerschmidt S., Polman J., et al. Microarray analysis in rat liver slices correctly predicts in vivo hepatotoxicity. Toxicol. Appl. Pharmacol. 2008, 229:300-309.
142. van Midwoud P.M., Groothuis G.M., Merema M.T., Verpoorte E. Microfluidic biochip for the perifusion of precision-cut rat liver slices for metabolism and toxicology studies. Biotechnol. Bioeng. 2010, 105:184-194.
143. van Midwoud P.M., Merema M.T., Verpoorte E., Groothuis G.M.M. Microfluidics enables small-scale tissue-based drug metabolism studies with scarce human tissue. J. Lab. Automot. 2011, 16:468-476.
144. van Midwoud P.M., Merema M.T., Verweij N., Groothuis G.M., Verpoorte E. Hydrogel embedding of precision-cut liver slices in a microfluidic device improves drug metabolic activity. Biotechnol. Bioeng. 2011, 108:1404-1412.
145. Schumacher K., Khong Y.-M., Chang S., Ni J., Sun W., Yu H. Perfusion culture improves the maintenance of cultured liver tissue slices. Tissue Eng. 2007, 13:197-205.
146. van Midwoud P., Janssen J., Merema M.T., de Graaf I., Groothuis G.M., Verpoorte E. On-line HPLC analysis system for metabolism and inhibition studies in precision-cut liver slices. Anal. Chem. 2011, 83:84-91.
147. Domansky K., Inman W., Serdy J., Dash A., Lim M.H.M., Griffith L.G. Perfused multiwell plate for 3D liver tissue engineering. Lab Chip 2010, 10:51-58.
148. Sung J.H., Shuler M.L. Microtechnology for mimicking in vivo tissue environment. Ann. Biomed. Eng. 2012, 40:1289-1300.
149. Lee P.J., Hung P.J., Lee L.P. An artificial liver sinusoid with a microfluidic endothelial-like barrier for primary hepatocyte culture. Biotechnol. Bioeng. 2007, 97:1340-1346.
150. Zhang M.Y., Lee P.J., Hung P.J., Johnson T., Lee L.P., Mofrad M.R.K. Microfluidic environment for high density hepatocyte culture. Biomed. Microdevices 2007, 10:117-121.
151. Toh Y.-C., Zhang C., Zhang J., Khong Y.M., Chang S., Samper V.D., et al. A novel 3D mammalian cell perfusion-culture system in microfluidic channels. Lab Chip 2007, 7:302-309.
152. Kim L., Toh Y.-C., Voldman J., Yu H. A practical guide to microfluidic perfusion culture of adherent mammalian cells. Lab Chip 2007, 7:681-694.
153. Wang Y., Toh Y.-C., Li Q., Nugraha B., Zheng B., Lu T.B., et al. Mechanical compaction directly modulates the dynamics of bile canaliculi formation. Integr. Biol. (Camb.) 2013, 5:390-401.
154. Zhang C., Zhao Z., Abdul Rahim N.A., van Noort D., Yu H. Towards a human-on-chip: culturing multiple cell types on a chip with compartmentalized microenvironments. Lab Chip 2009, 9:3185-3192.
155. Ong S.-M., Zhang C., Toh Y.-C., Kim S.H., Foo H.L., Tan C.H., et al. A gel-free 3D microfluidic cell culture system. Biomaterials 2008, 29:3237-3244.
156. Toh Y.-C., Lim T.C., Tai D., Xiao G., van Noort D., Yu H. A microfluidic 3D hepatocyte chip for drug toxicity testing. Lab Chip 2009, 9:2026-2035.
157. Zhang C., Chia S.-M., Ong S.-M., Zhang S., Toh Y.-C., van Noort D., et al. The controlled presentation of TGF-beta1 to hepatocytes in a 3D-microfluidic cell culture system. Biomaterials 2009, 30:3847-3853.
158. Goral V.N., Hsieh Y.-C., Petzold O.N., Clark J.S., Yuen P.K., Faris R.A. Perfusion-based microfluidic device for three-dimensional dynamic primary human hepatocyte cell culture in the absence of biological or synthetic matrices or coagulants. Lab Chip 2010, 10:3380.
159. Detzel C.J., Kim Y., Rajagopalan P. Engineered three-dimensional liver mimics recapitulate critical rat-specific bile acid pathways. Tissue Eng. A. 2011, 17:677-689.
160. Griffith L.G., Wu B., Cima M.J., Powers M.J., Chaignaud B., Vacanti J.P. In vitro organogenesis of liver tissue. Ann. N. Y. Acad. Sci. 1997, 831:382-397.
161. Griffith L.G., Naughton G. Tissue engineering-current challenges and expanding opportunities. Science 2002, 295:1009-1014.
162. Inman W., Domansky K., Serdy J., Owens B., Trumper D., Griffith L.G. Design, modeling and fabrication of a constant flow pneumatic micropump. J. Micromech. Microeng. 2007, 17:891-899.
163. Yates C., Shepard C.R., Papworth G., Dash A., Beer Stolz D., Tannenbaum S., et al. Novel three-dimensional organotypic liver bioreactor to directly visualize early events in metastatic progression. Adv. Cancer Res. 2007, 97:225-246.
164. Hwa A.J., Fry R.C., Sivaraman A., So P.T., Samson L.D., Stolz D.B., et al. Rat liver sinusoidal endothelial cells survive without exogenous VEGF in 3D perfused co-cultures with hepatocytes. FASEB J. 2007, 21:2564-2579.
165. Powers M.J., Griffith L.G. Adhesion-guided in vitro morphogenesis in pure and mixed cell cultures. Microsc. Res. Tech. 1998, 43:379-384.
166. Chung S., Sudo R., Mack P.J., Wan C.-R., Vickerman V., Kamm R.D. Cell migration into scaffolds under co-culture conditions in a microfluidic platform. Lab Chip 2009, 9:269-275.
167. Sudo R., Chung S., Zervantonakis I.K., Vickerman V., Toshimitsu Y., Griffith L.G., et al. Transport-mediated angiogenesis in 3D epithelial coculture. FASEB J. 2009, 23:2155-2164.
168. Chen M.B., Whisler J.a, Jeon J.S., Kamm R.D. Mechanisms of tumor cell extravasation in an in vitro microvascular network platform. Integr. Biol. (Camb.) 2013, 5:1262-1271.
169. Yamada M., Utoh R., Ohashi K., Tatsumi K., Yamato M., Okano T., et al. Controlled formation of heterotypic hepatic micro-organoids in anisotropic hydrogel microfibers for long-term preservation of liver-specific functions. Biomaterials 2012, 33:8304-8315.
170. Verhulsel M., Vignes M., Descroix S., Malaquin L., Vignjevic D.M., Viovy J.-L. A review of microfabrication and hydrogel engineering for micro-organs on chips. Biomaterials 2013, 35:1816-1832.
171. Khetan S., Guvendiren M., Legant W.R., Cohen D.M., Chen C.S., Burdick J.A. Degradation-mediated cellular traction directs stem cell fate in covalently crosslinked three-dimensional hydrogels. Nat. Mater. 2013, 12:458-465.
172. Olsen A.L., Bloomer S.A., Chan E.P., Gaca M.D.A., Georges P.C., Sackey B., et al. Hepatic stellate cells require a stiff environment for myofibroblastic differentiation. AJP Gastrointest. Liver Physiol. 2011, 301:G110-G118.
173. Mehta G., Williams C.M., Alvarez L., Lesniewski M., Kamm R.D., Griffith L.G. Synergistic effects of tethered growth factors and adhesion ligands on DNA synthesis and function of primary hepatocytes cultured on soft synthetic hydrogels. Biomaterials 2010, 31:4657-4671.
174. Lozoya O.A., Wauthier E., Turner R.A., Barbier C., Prestwich G.D., Guilak F., et al. Regulation of hepatic stem/progenitor phenotype by microenvironment stiffness in hydrogel models of the human liver stem cell niche. Biomaterials 2011, 32:7389-7402.
175. Lee M., Wu B.M. Recent advances in 3D printing of tissue engineering scaffolds. Methods Mol. Biol 2012, 257-267. Humana Press, Totowa, NJ.
176. Mironov V., Kasyanov V., Markwald R.R. Organ printing: from bioprinter to organ biofabrication line. Curr. Opin. Biotechnol. 2011, 22:667-673.
177. Mironov V., Visconti R.P., Kasyanov V., Forgacs G., Drake C.J., Markwald R.R. Organ printing: tissue spheroids as building blocks. Biomaterials 2009, 30:2164-2174.
178. Billiet T., Vandenhaute M., Schelfhout J., Van Vlierberghe S., Dubruel P. A review of trends and limitations in hydrogel-rapid prototyping for tissue engineering. Biomaterials 2012, 33:6020-6041.
179. Lutolf M.P., Hubbell J.A. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat. Biotechnol. 2005, 23:47-55.
180. Fang N., Sun C., Zhang X. Diffusion-limited photopolymerization in scanning micro-stereolithography. Appl. Physiol. A 2004, 79:1839-1842.
181. Feng L., Milner D.J., Xia C., Nye H.L.D., Redwood P., Cameron J.A., et al. Xenopus laevis as a novel model to study long bone critical-size defect repair by growth factor-mediated regeneration. Tissue Eng. A. 2011, 17:691-701.
182. Xia C., Fang N.X. 3D microfabricated bioreactor with capillaries. Biomed. Microdevices 2009, 11:1309-1315.
183. Derby B. Printing and prototyping of tissues and scaffolds. Science 2012, 338:921-926.
184. Baranski J.D., Chaturvedi R.R., Stevens K.R., Eyckmans J., Carvalho B., Solorzano R.D., et al. Geometric control of vascular networks to enhance engineered tissue integration and function. Proc. Natl. Acad. Sci. 2013, 110:7586-7591.
185. Warkiani M.E., Guan G., Luan K.B., Lee W.C., Bhagat A.A.S., Chaudhuri P.K., et al. Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells. Lab Chip 2014, 14:128-137.
186. Di L., Atkinson K., Orozco C.C., Funk C., Zhang H., Mcdonald T.S., et al. In vitro-in vivo correlation for low-clearance compounds using hepatocyte relay method. Drug Metab. Dispos. 2013, 41:2018-2023.
187. Xu H., Shuler M.L. Quantification of chemical-polymer surface interactions in microfluidic cell culture devices. Biotechnol. Prog. 2009, 25:543-551.
188. Wang J.D., Douville N.J., Takayama S., ElSayed M. Quantitative analysis of molecular absorption into PDMS microfluidic channels. Ann. Biomed. Eng. 2012, 40:1862-1873.
189. McGraw J., Waller D. Cytochrome P450 variations in different ethnic populations. Expert Opin. Drug Metab. Toxicol. 2012, 8:371-382.
190. Di Paolo A., Bocci G., Polillo M., Del Re M., Di Desidero T., Lastella M., et al. Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity. Curr. Drug Metab. 2011, 12:932-943.
191. Tang S.W., Lv X.Z., Chen R., Wu S.S., Yang Z.R., Chen D.F., et al. Lack of association between genetic polymorphisms of CYP3A4, CYP2C9 and CYP2C19 and antituberculosis drug-induced liver injury in a community-based Chinese population. Clin. Exp. Pharmacol. Physiol. 2013, 40:326-332.
192. Daly A.K. Pharmacogenomics of adverse drug reactions. Genome Med. 2013, 5:5.
193. Buechler C., Weiss T.S. Does hepatic steatosis affect drug metabolizing enzymes in the liver?. Curr. Drug Metab. 2011, 12:24-34.
194. Hellman B., Salehi A., Gylfe E., Dansk H., Grapengiesser E. Glucose generates coincident insulin and somatostatin pulses and antisynchronous glucagon pulses from human pancreatic islets. Endocrinology 2009, 150:5334-5340.
195. Stimson R.H., Mohd-Shukri N.A., Bolton J.L., Andrew R., Reynolds R.M., Walker B.R. The postprandial rise in plasma cortisol in men is mediated by macronutrient-specific stimulation of adrenal and extra-adrenal cortisol production. J. Clin. Endocrinol. Metab. 2014, 99:160-168.
196. Loryan I., Lindqvist M., Johansson I., Hiratsuka M., van der Heiden I., van Schaik R.H.N., et al. Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia. Eur. J. Clin. Pharmacol. 2012, 68:397-406.
197. Waxman D.J., Holloway M.G. Sex differences in the expression of hepatic drug metabolizing enzymes. Anal. Chem. 2009, 76:215-228.
198. Dhir R.N., Dworakowski W., Thangavel C., Shapiro B.H. Sexually dimorphic regulation of hepatic isoforms of human cytochrome P450 by growth hormone. J. Pharmacol. Exp. Ther. 2006, 316:87-94.
199. Dickmann L., Patel S., Rock D., Wienkers L.C., Slatter J.G. Inducibility of male-specific isoforms of cytochrome p450 by sex-dependent growth hormone profiles in hepatocyte cultures from male but not female rats 2006, 34:410-419.
200. Aitken A.E., Richardson T.A., Morgan E.T. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu. Rev. Pharmacol. Toxicol. 2006, 46:123-149.
201. Cosgrove B.D., Alexopoulos L.G., Hang T., Hendriks B.S., Sorger P.K., Griffith L.G., et al. Cytokine-associated drug toxicity in human hepatocytes is associated with signaling network dysregulation. Mol. Biosyst. 2010, 6:1195-1206.
202. Perogamvros I., Ray D.W., Trainer P.J. Regulation of cortisol bioavailability-effects on hormone measurement and action. Nat. Rev. Endocrinol. 2012, 8:717-727.
203. Schmitt C., Kuhn B., Zhang X., Kivitz A.J., Grange S. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin. Pharmacol. Ther. 2011, 89:735-740.
204. Dickmann L.J., Patel S.K., Rock D.A., Wienkers L.C., Slatter J.G. Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. Drug Metab. Dispos. 2011, 39:1415-1422.
205. Hang T.-C., Lauffenburger D.A., Griffith L.G., Stolz D.B. Lipids promote survival, proliferation, and maintenance of differentiation of rat liver sinusoidal endothelial cells in vitro. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 302:G375-G388.
206. Eckhardt B.L., Francis P.A., Parker B.S., Anderson R.L. Strategies for the discovery and development of therapies for metastatic breast cancer. Nat. Rev. Drug Discov. 2012, 11:479-497.
207. Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple-negative breast cancer. N. Engl. J. Med. 2010, 363:1938-1948.
208. Vander Heiden M.G. Exploiting tumor metabolism[U+202F]: challenges for clinical translation. J. Clin. Invest. 2013, 123.
209. Haibe-Kains B., El-Hachem N., Birkbak N.J., Jin A.C., Beck A.H., Aerts H.J.W.L., et al. Inconsistency in large pharmacogenomic studies. Nature 2013, 504:389-393.
210. Friedman S.L., Sheppard D., Duffield J.S., Violette S. Therapy for fibrotic diseases: nearing the starting line. Sci. Transl. Med. 2013, 5.
211. Schuppan D., Kim Y.O. Evolving therapies for liver fibrosis. J. Clin. Invest. 2013, 123:1887-1901.
212. Shulla A., Randall G. Hepatitis C virus - host interactions, replication, and viral assembly. Curr. Opin. Virol. 2013, 2:719-726.
213. Steenbergen R.H.G., Joyce M.A., Thomas B.S., Jones D., Law J., Russell R., et al. Human serum leads to differentiation of human hepatoma cells, restoration of very-low-density lipoprotein secretion, and a 1000-fold increase in HCV Japanese fulminant hepatitis type 1 titers. Hepatology 2013, 58:1907-1917.
214. Edwards S., Lalor P.F., Nash G.B., Rainger G.E., Adams D.H. Lymphocyte traffic through sinusoidal endothelial cells is regulated by hepatocytes. Hepatology 2005, 41:451-459.
215. Lalor P.F., Curbishley S.M., Adams D.H. Identifying homing interactions in T-cell traffic in human disease. Methods Mol. Biol. 2010, 616:231-252.
216. Sung J.H., Esch M.B., Prot J.-M., Long C.J., Smith A., Hickman J.J., et al. Microfabricated mammalian organ systems and their integration into models of whole animals and humans. Lab Chip 2013, 13:1201-1212.
217. Vozzi F., Heinrich J. Connected culture of murine hepatocytes and human umbilical vein endothelial cells in a multicompartmental bioreactor. Tissue Eng. A. 2008, 15:1291-1299.
218. Guzzardi M.A., Domenici C., Ahluwalia A. Metabolic control through hepatocyte and adipose tissue cross-talk in a multicompartmental modular bioreactor. Tissue Eng. A. 2011, 17:1635-1642.
219. Wagner I., Materne E.-M., Brincker S., Süßbier U., Frädrich C., Busek M., et al. A dynamic multi-organ-chip for long-term cultivation and substance testing proven by 3D human liver and skin tissue co-culture. Lab Chip 2013, 13:3538-3547.
220. van Midwoud P.M., Merema M.T., Verpoorte E., Groothuis G.M.M. A microfluidic approach for in vitro assessment of interorgan interactions in drug metabolism using intestinal and liver slices. Lab Chip 2010, 10:2778-2786.
221. Polakos N.K., Cornejo J.C., Murray D.A., Wright K.O., Treanor J.J., Crispe I.N., et al. Kupffer cell-dependent hepatitis occurs during influenza infection. Am. J. Pathol. 2006, 168:1169-1178.
222. Sewer M.B., Morgan E.T. Down-regulation of the expression of three major rat liver cytochrome P450S by endotoxin in vivo occurs independently of nitric oxide production. J. Pharmacol. Exp. Ther. 1998, 287:352-358.
223. Guarner F., Malagelada J.-R. Gut flora in health and disease. Lancet 2003, 361:512-519.
224. O'Hara A.M., Shanahan F. The gut flora as a forgotten organ. EMBO Rep. 2006, 7:688-693.
225. Lau K.S., Cortez-Retamozo V., Philips S.R., Pittet M.J., Lauffenburger D.A., Haigis K.M. Multi-scale in vivo systems analysis reveals the influence of immune cells on TNF-α-induced apoptosis in the intestinal epithelium. PLoS Biol. 2012, 10:e1001393.